Successful treatment of Raynaud's Syndrome with prostacyclin

J. J. Belch, P. Newman, J. K. Drury, H. Capell, P. Leiberman, W. B. James, C. D. Forbes, C. R. Prentice

    Research output: Contribution to journalArticlepeer-review

    47 Citations (Scopus)


    There is evidence to suggest that platelet activation occurs in Raynaud's syndrome. We evaluated the effect of prostacyclin (PGI2) a potent antiplatelet and vasodilator agent in 5 female patients with Raynaud's syndrome. Outpatient visits were made at weekly intervals for 4 weeks. At the first visit buffer solution (Wellcome Laboratories) was infused intravenously for 5 hrs, thereafter three five hr infusions of PGI2 at a peak dose of 10 ng/Kg/min were given. Six weeks after the infusions patients were reviewed. Symptomatic improvement, including healing of ischaemic ulcers, occurred in 4 out of 5 patients. Thermography confirmed an increase in hand temperature after PCI2. Subjective and objective improvement has persisted for at least 6 weeks after the last treatment.
    Original languageEnglish
    Pages (from-to)255-6
    Number of pages2
    JournalThrombosis and Haemostasis
    Issue number3
    Publication statusPublished - 1981


    Dive into the research topics of 'Successful treatment of Raynaud's Syndrome with prostacyclin'. Together they form a unique fingerprint.

    Cite this